Ebola vaccines elicit yearlong immune response in Liberia trial.

Ebola vaccines elicit yearlong immune response in Liberia trial. Two candidate Ebola virus vaccines elicited immune responses that were mostly maintained through 1 year in a large clinical trial in Liberia, according to findings published in The New England Journal of Medicine. The trial, which took place during the 2014-2016 West African Ebola epidemic, evaluated the performance of two vaccines developed in the United States and Canada. One of the two vaccines — rVSV∆G-ZEBOV-GP (Merck) — was 100% effective at preventing Ebola in an earlier trial in Guinea. The vaccine was also used during a flare-up of Ebola in Guinea last year — the first time an Ebola vaccine has ever been used in an outbreak setting outside a clinical trial. The vaccine was approved for use during a recent outbreak in the Democratic Republic of the Congo but was not needed. Ebola